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Background: Placenta-mediated pregnancy complications include pre-eclampsia, late pregnancy loss, placental
abruption, and the small-for-gestational age newborn. They are leading causes of maternal, fetal, and neonatal
morbidity and mortality in developed nations. Women who have experienced these complications are at an
elevated risk of recurrence in subsequent pregnancies. However, despite decades of research no effective strategies
to prevent recurrence have been identified, until recently. We completed a pooled summary-based meta-analysis
that strongly suggests that low-molecular-weight heparin reduces the risk of recurrent placenta-mediated
complications. The proposed individual patient data meta-analysis builds on this successful collaboration. The
project is called AFFIRM, An individual patient data meta-analysis oF low-molecular-weight heparin For prevention
of placenta-medIated pRegnancy coMplications.
Methods/Design: We conducted a systematic review to identify randomized controlled trials with a low-molecular-
weight heparin intervention for the prevention of recurrent placenta-mediated pregnancy complications.
Investigators and statisticians representing eight trials met to discuss the outcomes and analysis plan for an
individual patient data meta-analysis. An additional trial has since been added for a total of nine eligible trials. The
primary analyses from the original trials will be replicated for quality assurance prior to recoding the data from each
trial and combining it into a common dataset for analysis. Using the anonymized combined data we will conduct
logistic regression and subgroup analyses aimed at identifying which women with previous pregnancy complications
benefit most from treatment with low-molecular-weight heparin during pregnancy.
Discussion: The goal of the proposed individual patient data meta-analysis is a thorough estimation of treatment
effects in patients with prior individual placenta-mediated pregnancy complications and exploration of which
complications are specifically prevented by low-molecular-weight heparin.
Systematic review registration: PROSPERO (International Prospective Registry of Systematic Reviews) 23 December
2013, CRD42013006249
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Placenta-mediated pregnancy complications include pre-
eclampsia (PE), late pregnancy loss, placental abruption
and the small-for-gestational age (SGA) newborn. We
completed a pooled summary-based meta-analysis that
strongly suggests that low-molecular-weight heparin
(LMWH) reduces the risk of placenta-mediated com-
plications in subsequent pregnancies [1].
A successful pregnancy requires the development of
adequate placental circulation. It has been hypothesized
that thrombosis in the placental bed is at least partially
responsible for placenta-mediated pregnancy complica-
tions [2-4]. It has also been suggested that these compli-
cations are the result of abnormal placental development
with underdeveloped placental vasculature or placental
inflammation [5,6]. These complications represent an
important health problem because they are common,
affecting more than one in six pregnancies [7], and often
have a devastating outcome for the affected women, their
unborn children, their families, and society. Specifically, PE
(characterized by a new onset of elevated blood pressure
and proteinuria during pregnancy) is one of the most com-
mon causes of maternal mortality in the developed world
[8-11]. SGA newborns often suffer longterm effects includ-
ing developmental delay, poor school performance, and a
significantly lower likelihood of academic and professional
success [12-14]. Fetal loss is a devastating event for preg-
nant women and their families. Placental abruption (separ-
ation of the placenta from the uterus before birth) can, in
the most severe cases, lead to maternal hemorrhage with
the risk of transfusion and both maternal and fetal death.
The risk of recurrent placenta-mediated pregnancy
complications in subsequent pregnancies is substantial.
For example, women with prior severe PE will have a 25
to 65% risk of recurrent PE, a 3% risk of placental abrup-
tion, and a 10% risk of SGA (<10th percentile) [15,16].
These complications may be multiple (for example both
PE and SGA) and not isolated to the placenta-mediated
complication experienced in a prior pregnancy [15,17].
There are no highly effective preventative strategies that
can be used in subsequent pregnancies. Aspirin offers
small relative risk reductions in patients with prior PE
and SGA, however, it may be more effective at reducing
risk (approximately a 40% reduction) if started early in
the pregnancy (before 16 weeks) [18,19]. There are no
proven preventative strategies for the other complications.
It has been postulated that anticoagulants might prevent
placenta-mediated pregnancy complications by reducing
placental thrombosis and/or affecting maternal coagula-
tion activation or inflammation. Recent randomized con-
trolled trials (RCTs) conducted to determine if LMWH
can prevent recurrent placenta-mediated pregnancy com-
plications suggest an important treatment effect [20-24],
but this finding has not been universal [25].Although it appears that LMWH is a promising ther-
apy in the prevention of placenta-mediated pregnancy
complications, there are disadvantages to the premature
adoption of this intervention without sufficient evidence
of benefit. If LMWH is used universally for all women
with prior placenta-mediated pregnancy complications,
we may be intervening unnecessarily and exposing women
to a risk of undesirable and potentially fatal, albeit rare,
side effects (major bleeding, heparin-induced thrombo-
cytopenia, osteoporotic fractures, withholding of epidural
analgesia due to fear of causing epidural hematoma, and
paralysis) [26,27]. Less serious side effects including skin
reactions, minor bleeding, and transient elevations in liver
enzymes are more commonly experienced [28,29]. Ther-
apy is also associated with cost and inconvenience since
the drug is expensive and is administered by injection
either once or twice a day. Therefore, it is necessary to
answer the question as to who benefits from LMWH
prophylaxis during pregnancy and to determine the nature
and magnitude of these benefits more precisely. The indi-
vidual patient data meta-analysis (IPDMA) has the poten-
tial to answer these important questions and determine
the risk/benefit ratio of therapy for various subgroups
of women.
The composite outcome, including all placenta-medi-
ated pregnancy complications, that is used in many RCTs
is heterogeneous and not all individual outcomes can be
considered equally serious in terms of potential conse-
quences for the mother and newborn. For example, late
term pre-eclampsia is clinically less worrisome since the
symptoms tend to be less severe and generally resolve with
delivery. Conversely, women who develop pre-eclampsia
earlier in the pregnancy have more serious clinical conse-
quences including a greater risk of maternal and neonatal
death. Our pooled summary meta-analysis suggests that
LMWH may prevent severe pre-eclampsia and early pre-
eclampsia with less of an effect on late onset pre-eclampsia
[1]. Confirmation of these findings is extremely important
for clinicians treating these women and has direct relevance
for clinical practice worldwide.
There are many challenges associated with recruiting
pregnant women to RCTs with a drug intervention
including: the biases of clinicians either for or against the
therapy (based on insufficient evidence of benefit and lack
of knowledge about potential risk); the concerns of the
pregnant woman and her family about the health and
safety of the mother and baby; and the demands during
pregnancy of attending additional appointments and in-
vestigations associated solely with study participation [1].
Furthermore, the pharmaceutical industry often excludes
pregnant women from trials due to liability concerns. As a
result, there is a dearth of RCTs evaluating LMWH in this
population compared to other patient groups (such as
oncology or orthopedic surgery). Those RCTs that do exist
Rodger et al. Systematic Reviews 2014, 3:69 Page 3 of 11
http://www.systematicreviewsjournal.com/content/3/1/69are all academically driven and may not have the same
financial and human resources that are available to trials
that are sponsored by the pharmaceutical industry. There-
fore, meta-analysis is an essential tool that allows for greater
statistical power by pooling the existing small RCTs evalu-
ating LMWH for the prevention of placenta-mediated
pregnancy complications.
Our recent pooled summary-based meta-analysis of six
RCTs (Table 1) included 848 pregnant women with a
history of pre-eclampsia, a SGA neonate (<10th percentile),
placental abruption, or late pregnancy loss (more than
12 weeks gestation) in a previous pregnancy [1]. The pri-
mary finding was that 67 out of 358 (18.7%) women taking
LMWH during pregnancy had recurrent severe placenta-
mediated pregnancy complications, as compared with 127
out of 296 (42.9%) women with no LMWH (relative risk
reduction 48% (95% CI 14 to 68%; (I2 69%). However, since
the meta-analysis results apply to a heterogeneous group
of women with a mixture of placenta-mediated pregnancy
complications of varying prior severity and the primary
outcome for the meta-analysis was a composite of all
placenta-mediated complications (also of varying severity),
it is not clear which subgroups of women derive the most
benefit from LMWH (which outcomes are reduced and
which severity of outcomes are impacted). Before recom-
mendations for clinical practice can be advocated, it is
necessary to conduct more detailed analyses of the existing
data to determine potential benefits for subgroups of
women, to adjust for important baseline characteris-
tics of participants, and to explore other treatment-related
reasons for the reported heterogeneity (for example spe-
cific LMWH drug (dalteparin, nadroparin or enoxaparin),
LMWH dose, gestational age when drug was initiated, and
co-interventions such as concomitant ASA use).
IPDMA has been proposed as an advantageous meth-
odological approach when subgroup analyses are hypothe-
sized to be clinically relevant. Analyzing original data from
individual patients makes use of a much richer dataset
and has greater statistical power than conventional meta-
analysis [31,32]. Furthermore, for this project, IPDMA will
allow for adjustment for covariates that are known to be
important in the recurrence of placenta-mediated preg-
nancy complications. Such an analysis will also enable us
to explore clinical, methodological, and statistical hetero-
geneity more robustly. IPDMA is an attractive method to
answer our study questions since it ‘dramatically and con-
sistently’ has more power to detect interactions between
risk groups [33].
Methods/Design
Research questions
The primary research question is: Which women with pre-
vious placenta-mediated pregnancy complications have a
reduction in the risk of future complications when treatedwith LMWH during pregnancy? Secondary research
questions are: Which of the placenta-mediated preg-
nancy complications are avoided? Are severe and/or
early onset or non-severe and/or late onset complica-
tions avoided? Does LMWH cause major bleeding in
women with prior placenta-mediated pregnancy com-
plications? And, are any other side effects increased by
LMWH use in women with prior placenta-mediated preg-
nancy complications (thrombocytopenia, osteoporotic
fractures or allergic reactions)?
The proposed project is called AFFIRM (An individual
patient data meta-analysis oF low-molecular-weight
heparin For prevention of placenta-medIated pReg-
nancy complications), PROSPERO registration number:
CRD42013006249. We will synthesize individual patient
data from RCTs of LMWH for the prevention of recurrent
placenta-mediated pregnancy complications. The overall
objective of the meta-analysis is to directly inform clinical
practice and the development of clinical practice guidelines.
The study is coordinated by the Clinical Epidemiology
Program at the Ottawa Hospital Research Institute. Con-
ceptually, the research approach involves four sequential
phases: a systematic review, knowledge synthesis planning,
data extraction and analysis, and interpretation of results
and knowledge translation. The first two phases have been
completed and are therefore described below in the past
tense. No data have been extracted or recoded for the
common dataset and no statistical analyses have been per-
formed; these steps are outlined in the future tense.
Systematic review
Electronic search strategies were developed and tested
through an iterative process by an experienced medical
information specialist in consultation with the review
team. The strategy was peer-reviewed prior to execution
by an experienced information specialist using the Peer
Review of Electronic Search Strategies (PRESS) checklist
[34]. The following search was conducted in May 2013:
using the OVID platform, we searched Ovid MEDLINE™,
Ovid MEDLINE™ In-Process & Other Non-Indexed
Citations, and EmbaseClassic + Embase (strategy included
as Additional file 1). We also searched the Cochrane
Library on Wiley (including CENTRAL, Cochrane Data-
base of Systematic Reviews, DARE, and HTA). Clini-
calTrials.gov and the WHO International Clinical Trials
Registry were searched to identify relevant in-process
and completed trials. Strategies utilized a combination
of controlled vocabulary (such as ‘hypertension, pregnancy-
induced’, ‘placental insufficiency’, ‘heparin, low-molecular-
weight’) and keywords (pre-eclampsia, abruption, and
LMWH). Vocabulary and syntax were adjusted across
databases. Animal studies were excluded but there
were no language or date restrictions on any of the
searches. We sought additional references through hand-
Table 1 Previously identified trials that meet the inclusion criteria for AFFIRM
Study name &
first author
Year Country & sample size Participants Intervention & control Outcomes Commitment to
participate in IPDMA
TIPPS* [30] Rodger 2013 Canada, Multinational
N = 292
Thrombophilia + previous high risk criteria Dalteparin 5000 IU to 20 wks
then 10,000 IU to 36 wks vs
no Dalteparin
PE, SB, abruption, SGA <10th
percentile
Yes
FRUIT [20] de Vries 2012 Netherlands,
Multinational N = 139
Prior early onset PE (n = 107) and/or
SGA <10th percentile (n = 94)
Dalteparin 5000 IU + ASA vs ASA PE prior to 34 weeks GA Yes
HAPPY [25] Martinelli 2012 Italy, Multi-center
N = 135
Prior PE (n = 52), prior loss >15 weeks
(n = 49), prior SGA <10th percentile
(n = 28) or prior abruption (n = 5)
Nadroparin 3800 IU vsno Nadroparin PE, Loss >15 weeks GA,
SGA <10thpercentile and/or abruption
Yes
NOH-PE [21] Gris 2011 France, Single center
N = 224
Prior severe PE (n = 224) Enoxaparin 4000 IU + ASA vs ASA PE, SB, abruption, SGA <5th percentile Yes
NOH-AP [24] Gris 2010 France, Single center
N = 160
Prior abruption (n = 160; 70 with PE) Enoxaparin 4000 IU+/−ASA vs +/−ASA PE, SB, abruption, SGA <5thpercentile Yes
Rey [23] 2009 Canada, Multi-center
N = 116
Prior early PE (n = 60), prior abruption
(n = 16), prior SGA <5th percentile (n = 21),
loss >12 weeks (n = 17)
Dalteparin 5000 IU+/−ASA vs +/−ASA PE, SB, abruption, SGA <5th percentile Yes
Mello [22] 2005 Italy, Single center
N = 80
Prior PE with ACE DD (n = 80) Dalteparin 5000 IU vsno Dalteparin PE, SGA <10th percentile Unable to contact
ASA = aspirin; GA = gestational age; IPDMA = individual patient data meta-analysis; IPDMA = individual patient data meta-analysis; PE = pre-eclampsia; RCT = randomized controlled trial; SB = stillbirth;
SGA = small-for-gestational age.
Trial Names:
TIPPS = Thrombophilia In Pregnancy Prophylaxis Study *accepted for publication in the Lancet.
FRUIT = FRactionated heparin in pregnant women with a history of Utero-placental Insufficiency and Thrombophilia.
NOH-AP = Nîmes Obstetricians and HAematologist – abruptio placentae.
NOH-PE = Nîmes Obstetricians and HAematologist - pre-eclampsia.
HAPPY = Heparin in pregnant women with Adverse Pregnancy outcome to improve the rate of successful PregnancY.
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sults are summarized in a preferred reporting items for
systematic reviews and meta-analyses (PRISMA) diagram
(Figure 1) and details of potentially eligible trials are pro-
vided in Tables 2 and 3.
Inclusion criteria
RCTs with an LMWH intervention for the prevention of
recurrent placenta-mediated pregnancy complications were
eligible. The study population of interest included currently
pregnant women with prior pregnancies complicated by
one or more of the following: PE, placental abruption, SGA
newborn (<10th percentile), pregnancy loss after 16 weeks
gestation or two losses after 12 weeks gestation. The
principal investigators of potentially eligible trials identi-
fied by the systematic review (see Tables 1, 2 and 3) wereRecords idenﬁed through
database searching
(Cochrane = 56
Embase = 236
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Figure 1 PRISMA flow diagram of AFFIRM’s systematic review. IPD = in
PRISMA = preferred reporting items for systematic reviews and meta-analyscontacted via email to request additional information
about the study population. Once eligibility was con-
firmed, investigators were invited to participate in the
IPDMA and attend the AFFIRM project planning meet-
ing. The lead investigators of the largest and most recently
completed trials agreed to contribute individual patient
data to this collaboration. Data from two small trials
[22,41] were not included because the investigators did
not respond; in one of these trials only a small proportion
of the total study population would have been eligible to
contribute data to AFFIRM [41]. Some of the women in
the Scottish Pregnancy Intervention Study (SPIN) trial
would have been eligible for inclusion in AFFIRM, how-
ever, the trial database does not include sufficient detail
about the timing of previous pregnancy losses to deter-
mine the eligibility of individual participants [39].Addional records idenﬁed
through trial registries
(ClinicalTrials.gov = 93
WHO registry = 1)
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Table 2 Potentially eligible published trials identified by AFFIRM’s systematic review
Study name &
first author
Year Country &
sample size
Participants Intervention & control Relevant outcomes Comment re:
inclusion in IPDMA
ETHIG II
*Schleussner [35]
Abstract
2013
Germany N = 449 Recurrent
pregnancy loss
Dalteparin 5000
IU + vitamins vs
multivitamins
Intact pregnancy at
24 wks GA; PE; IUGR <5th
percentile; abruption
Yes
Giancotti [36] 2012 Italy N = 167
(pregnant)
Recurrent
pregnancy loss
Enoxaparin 40 mg vs
Enoxaparin 40 mg +
ASA vs ASA
Live births Not eligible
(All losses <12
weeks GA)
Salman [37] Abstract
2012
Egypt N = 150 Recurrent
pregnancy loss
Tinzaparin 4500 IU vs
folic acid
Continuation of
pregnancy after
20 weeks
Not eligible
(All women with
early losses)
HABENOX [38]
Visser
2011 Finland, Sweden,
Netherlands N = 207
Women with
recurrent early
or late miscarriage
Enoxaparin 40 mg vs
Enoxaparin 40 mg +
ASA vs ASA
Live birth rate; PE;
IUGR <2 SD; abruption
Yes
SPIN [39] Clark 2010 UK, New Zealand
N = 294
Recurrent
pregnancy loss
Enoxaparin 40 mg + ASA
vsno drug
Pregnancy loss GA of past losses
not available centrally
ALIFE [40] Kaandorp 2010 Netherlands
N = 299 (pregnant)
Recurrent
pregnancy loss
Nadroparin 2850 IU +
ASA vs ASA vs placebo
Pregnancy loss,
SGA <10th percentile;
PE; HELLP; abruption
Yes
HepASA [41] Laskin 2009 Canada N = 88
Terminated at
interim analysis
Recurrent
pregnancy loss
Dalteparin 5000 IU +
ASA vs ASA
Live births Unable to contact
ASA = aspirin; GA = gestational age; HELLP = HELLP syndrome (hemolysis, elevated liver enzymes, low platelet count); IPDMA = individual patient data meta-analysis;
IUGR = intrauterine growth restriction; PE = pre-eclampsia; SB = stillbirth; SGA = small-for-gestational age.
Trial Names:
SPIN = Scottish Pregnancy Intervention Study; HepASA = Low Molecular Weight Heparin and Aspirin in the Treatment of Recurrent Pregnancy Loss.
ALIFE = Anticoagulants for Living Fetuses.
HABENOX = Low Molecular Weight Heparin and/or Aspirin in Prevention of Habitual Abortion.
ETHIG II = Effectiveness of Dalteparin Therapy as Intervention in Recurrent Pregnancy Loss *final results in preparation for publication.
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A crucial step in the success of the project was the de-
velopment of the knowledge synthesis and knowledge
translation plans. A full-day review team meeting was
held in Amsterdam on 4 July 2013. The purpose was to
allow for extensive discussion and consensus-reaching
on important study variables and outcomes and to con-
sider strategies for merging the existing datasets in a
centralized database. Participants included the principal
investigators of the included RCTs and statisticians with
in-depth knowledge of the trial data. The principal in-
vestigators are all practising clinicians (obstetricians andTable 3 Potentially eligible registered trials identified by AFF
Study name &
principal investigator
Identified through Participants
EPPI McLintock Ongoing RCT (New Zealand)
ANZCTR registry
ACTRN12609000699268
Prior PE or SGA
HEPEPE Haddad Ongoing RCT (France)
Clinicaltrials.gov NCT00986765
Prior severe
pre-eclampsia
HOPPE Llurba Ongoing RCT (Spain)
Clinicaltrials.gov NCT01388322
Prior severe PE, SGA
loss, or abruption
ASA = aspirin; IPDMA = individual patient data meta-analysis; IUGR = intrauterine gro
Trial Names:
EPPI = Enoxaparin for the Prevention of Preeclampsia and Intrauterine growth restri
HEPEPE = Prevention of Maternal and Perinatal Complications by Enoxaparin in Wom
HOPPE = Low Weight Heparin prOphylaxis for Placental Mediated Complications ofhematologists) who are also knowledge users in this
clinical area.
Outcome measures
The detailed definitions for the IPDMA outcomes
were agreed upon by investigator consensus at the
face-to-face meeting. The definitions and diagnostic
criteria for each outcome variable are documented in
a data dictionary and the research protocol. These defini-
tions, which have been reviewed by all investigators, allow
standardization across studies and decrease the potential
for bias.IRM’s systematic review
Intervention & control Outcomes Comment re:
inclusion in IPDMA
Enoxaparin 40 mg vs
standard care
PE, SGA Recruitment ongoing
Enoxaparin 4000 IU + ASA
vs ASA
PE; IUGR; abruption;
perinatal death
Recruitment ongoing
, Enoxaparin 40 mg or
80 mg (weight-based)
vsno intervention
PE; IUGR; abruption;
fetal death
Recruitment ongoing
wth restriction; PE = pre-eclampsia; SGA = small-for-gestational age.
ction.
en With Previous Severe Preeclampsia (original title is French).
PrEgnancy.
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including four pregnancy complications: early-onset or
severe pre-eclampsia, birth of a small-for-gestational age
newborn with a birth weight <5th percentile, placental
abruption, and late pregnancy loss. To qualify as a primary
outcome event, the pregnancy complication must satisfy
one or more predefined criteria. Early onset pre-eclampsia
is diagnosed at less than 34 weeks’ gestation. Severe
pre-eclampsia is characterized by at least one criterion
indicative of severe disease; these are, a systolic blood pres-
sure ≥ 160 mm Hg or diastolic blood pressure ≥110 mm
Hg, proteinuria > 0.5 g/24 hours, elevated liver enzymes
(more than two times the local upper range of normal),
platelets < 100 × 109/L, pulmonary edema, seizures (eclamp-
sia), headache or other neurological manifestations (stroke,
intracranial hemorrhage, cerebral edema, hyperreflexia, and
visual impairment), coagulopathy, oliguria (<30 ml/hr)
or HELLP syndrome (hemolysis, elevated liver enzymes,
low platelet count). Birth of a small-for-gestational age
newborn with a birth weight <5th percentile is deter-
mined using local gender and gestational age specific birth
weight charts. The placental abruption outcome requires
a clinical diagnosis of placental abruption leading to deliv-
ery. A late pregnancy loss occurs at or after 20 weeks of
gestation and cannot be explained by other factors, includ-
ing fetal chromosomal abnormalities, maternal infection,
cervical insufficiency or incompetence, or an intentional
termination of the pregnancy.
Nineteen secondary outcomes have been defined for
AFFIRM, including the four individual components of the
primary outcome: severe or early-onset pre-eclampsia,
birth of a small-for-gestational age newborn <5th percent-
ile, placental abruption and late pregnancy loss, all as out-
lined above. Pre-eclampsia (non-severe) is characterized
by a systolic blood pressure ≥140 mm Hg or diastolic
blood pressure ≥90 mm Hg and proteinuria >0.3 g/
24 hours. A diagnosis of HELLP syndrome required 3
criteria, hemolysis [lactate dehydrogenase (LDH) > 600 IU/L
or serum bilirubin >1.2 mg/dl] an abnormal elevation of
liver enzymes (more than two times the local upper
range of normal), and platelets <100 × 109/L. Preterm
delivery <34 weeks and < 37 weeks are pre-specified out-
comes. A perinatal loss is any fetal or neonatal death
at over 20 weeks gestational age and less than or
equal to 28 days post-partum and neonatal mortality is
considered any neonatal death after birth and less than or
equal to 28 days post-partum. Birth of a small-for-gesta-
tional age newborn <10th percentile is determined based
on local gender and gestational age specific birth weight
charts.
Adverse maternal outcomes include thrombocytopenia,
defined as a platelet count <75,000 × 109/L, and bleeding
outcomes at various time points. Antepartum major
bleeding is defined using the criteria proposed by theInternational Society on Thrombosis and Haemostasis
(ISTH) [42]. That is, clinical or radiological evidence
of bleeding with at least one of the following criteria:
associated with a fall in hemoglobin of 2 g/dL (1.24 mmol/L)
or more; or a requirement for transfusion of two or more
units of red blood cells or whole blood; or symptomatic
bleeding occurring in a critical site: intracranial, intra-
spinal, intraocular, pericardial, intra-articular, intramuscu-
lar with compartment syndrome, or retroperitoneal, or
was considered to have contributed to maternal death.
Peripartum major bleeding is hemorrhage occurring after
the onset of labour or start of surgical delivery and within
24 hours postpartum that meets at least one of the follow-
ing: necessitating a surgical procedure, or associated with
a fall in hemoglobin of 4 g/dL (2.48 mmol/L) or more, or
a requirement for transfusion of two or more units of red
blood cells or whole blood, or estimated peripartum blood
loss >1000 ml, or considered to have contributed to ma-
ternal death. Peripartum minor bleeding is hemorrhage
occurring after the onset of labour or start of surgical
delivery and within 24 hours postpartum that does not
meet any criterion above and with estimated peripartum
blood loss between 500 and 1000 ml. Postpartum major
bleeding is clinical or radiological evidence of bleeding
occurring between 24 hours and 6 weeks postpartum
and meeting at least one of the following ISTH cri-
teria: associated with a fall in hemoglobin of 2 g/dL
(1.24 mmol/L) or more, or a requirement for transfu-
sion of two or more units of red blood cells or whole
blood, or symptomatic bleeding occurring in a critical
site: intracranial, intraspinal, intraocular, pericardial, intra-
articular, intramuscular with compartment syndrome, or
retroperitoneal, or considered to have contributed to
maternal death.
An allergic reaction to LMWH is a reaction following
the administration of LMWH that results in anaphylaxis
or a rash requiring discontinuation of the allocated
LMWH. Heparin-induced thrombocytopenia (HIT) is
defined as a clinical diagnosis of HIT and a minimum of
a positive PF4 HIT ELISA assay. The venous thrombo-
embolism outcome includes deep vein thrombosis (DVT)
and/or pulmonary embolism. The criteria for diagnosis of
DVT are venography demonstrating a constant intralum-
inal filling defect in the deep veins above the trifurcation
of the popliteal vein or compression ultrasound revealing
a non-compressibility of a venous segment above the tri-
furcation of the popliteal vein. Diagnosis of distal, below
the knee DVT, is by either venography or compression
ultrasound. Diagnostic criteria for pulmonary embolism
are pulmonary angiography demonstrating a constant
intraluminal filling defect or a cutoff of a vessel more than
2.5 mm in diameter, or ventilation/perfusion (V/Q scan)
indicating high-probability, or pulmonary embolism found
at autopsy.
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The definitions for each variable to be included in
AFFIRM’s common dataset are documented in a data
dictionary to allow standardization across studies and
decrease the potential for misclassification and bias. A
template for the common dataset has been developed
in Microsoft Excel and will be provided to the principal
investigator of each included trial. Recoded anonymized
individual patient data from each of the trials will populate
the Excel template. The recoded datasets for each of the
individual trials will be saved on an IronKey™ USB flash
drive and sent by courier to the coordinating center in
Ottawa.
The AFFIRM common dataset will include individual
patient data in 10 pre-defined categories: administrative
and demographic data, thrombophilia, maternal medical
history, pregnancy history, current pregnancy and deliv-
ery, infant data, pre-eclampsia outcome, other outcome
events, intervention and treatment during pregnancy,
and adverse events.Data synthesis, validation and analysis
Once the individual participant data from the primary
studies have been merged in the common dataset, descrip-
tive analyses will be conducted to identify data outliers,
missing data, and unexpected inconsistencies. The project
coordinator will prepare data clarification reports and will
communicate with the principal investigators or their del-
egates to resolve these queries. Next, we plan to conduct
preliminary analyses aimed at replicating the findings of
the individual published studies, to validate the centralized
database and data importation. Once the IPDMA team is
satisfied with the merged dataset, the database will be
locked and the planned analyses for the IPDMA synthesis
will be conducted.
The individual patient data will be analyzed in a simi-
lar manner to an RCT, however, the analysis will account
for clustering at the study level. The primary analysis
will include all women who are eligible for AFFIRM and
will examine the risk of the primary composite outcome
in the treatment (LMWH) and control arms based on
intention-to-treat. Secondary univariate analyses will be
done for each of the pregnancy complications included
in the composite outcome. On-treatment sensitivity ana-
lyses will be conducted for the primary and secondary
outcomes.Subgroup analyses
We have planned several subgroup analyses; these were
selected because they are clinically plausible and there is
evidence that they may be relevant. If certain subgroups
are found to be small (≤5 subjects) we will merge sub-
groups as appropriate.Women will be analyzed in subgroups according to the
previous pregnancy complications that were experienced.
Prior pre-eclampsia subgroups are any pre-eclampsia,
severe pre-eclampsia, early-onset pre-eclampsia, and se-
vere or early onset pre-eclampsia. Subgroups according to
prior SGA are SGA <10th percentile, SGA <5th percentile,
SGA <3rd percentile, prior pre-eclampsia and SGA <10th
percentile, prior pre-eclampsia and SGA <5th percentile,
prior pre-eclampsia and SGA <3rd percentile. Subgroups
of women with prior placental abruption are any pla-
cental abruption, placental abruption leading to deliv-
ery <37 weeks’ gestation, placental abruption leading
to delivery < 34 weeks’ gestation, and placental abruption
with pre-eclampsia. Participants will be grouped for
analysis according to the gestational age of prior preg-
nancy loss: >12 weeks’ gestation, >16 weeks’ gestation,
and >20 weeks’ gestation. Demographic subgroups are
according to maternal age (<35 years or ≥35 years) and
ethnic group (Caucasian, Black, Asian or other).
Women will be grouped according to personal character-
istics and risk factors. For thrombophilia the subgroups are
women with weak thrombophilia (Factor V Leiden [FVL]
or prothrombin gene mutation [PGM]); moderate throm-
bophilia (protein C deficiency, protein S deficiency); strong
thrombophilia (antithrombin deficiency, antiphospholipid
antibodies, combined thrombophilia ≥1 type, homozygous
FVL or PGM); or no thrombophilia. Participants will be
grouped according to personal history of venous throm-
boembolism (VTE), family history of VTE, and no VTE
history
Quality assessment will be conducted for all eligible
studies using the tool for assessing risk of bias from the
Cochrane Handbook for reviews of interventions [43]
and reported on a study level. These assessments will
also be used to inform subgroup analyses and sensitivity
analyses to explore whether these biases may have affected
the IPDMA analysis. We plan to examine the randomi-
zation integrity once the data from the original trials have
been combined. We will endeavour to compare the
original randomization lists with actual randomization to
test the integrity of the allocation concealment. We will
also compare the baseline characteristics of participants
who have been randomized to the LMWH and no
LMWH groups at the study level and aggregate level to
see if there are imbalances between the groups that may
suggest a lack of integrity in randomization processes.
Knowledge translation
Once the results of the analyses are available, they will
be circulated to all investigators and collaborators and a
teleconference will be scheduled to discuss the findings
and their interpretation. Regardless of the IPDMA results,
they will be disseminated. Dr Shannon Bates is the princi-
pal knowledge user for this project. She will provide input
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knowledge translation phase of the study. The princi-
pal investigators of the identified eligible RCTs (Drs Rey,
Martinelli, de Vries, Gris, Rodger, Middeldorp, Schleussner,
and Kaaja) are all experienced researchers and also prac-
ticing physicians who are knowledge users. Furthermore,
these team members are all involved in leadership roles in
their institutions and countries, including practice guide-
line development, and have the potential to considerably
influence the international community of healthcare pro-
viders in a variety of settings.
The strategies for knowledge translation will rely heavily
on the input from all involved knowledge users and will
take into consideration the suitability of proposed media
and/or approach for different practice settings and inter-
national contexts. Traditional methods, such as publica-
tion in a peer-reviewed journal, geared towards either a
generalist or specialist audience, will be employed. Results
will also be presented at international meetings; it is
anticipated that knowledge users (clinicians) in hemato-
logy, obstetrics, and family medicine will be targeted. In
addition, patient advocacy and education groups (such
as the Pre-eclampsia Foundation, the North American
Thrombosis Forum, and Thrombosis Canada) will be
provided with the results in a language and format
suitable to a non-medical audience.Discussion
This IPDMA will permit the investigators to explore
which women within the heterogeneous group of patients
with placenta-mediated complications benefit and which
women do not benefit from low-molecular-weight heparin
injections throughout pregnancy.Ethics, privacy and security
The subjects in each of the RCTs all provided informed
consent to participate in the original trial. We will not
be seeking individual consent for the secondary use of
the data for the following reasons: the objectives of the
IPDMA are consistent with the original trials, there are
no risks or benefits associated with this analysis, no
identifying information will be transferred, and it would
be logistically time consuming and, in some cases, impos-
sible to contact the women who participated. In order to
ensure patient confidentiality any identifying information
will be removed from the original dataset before it is
transferred. The IronKey™ flash drive includes numerous
security features including hardware-based encryption, a
random password generator, two-factor authentication,
and a self-destruct mechanism which make it extremely
unlikely that the dataset can be accessed by anyone other
than the intended recipient. Once the data are merged in
Ottawa in the common database, they will be stored onthe research institute’s network which has multiple secur-
ity features and regular backup procedures in place.Limitations and challenges
One relevant potential drawback of IPDMA is biased
pooling of data. Bias can be introduced when eligible stud-
ies are missed, when authors do not provide their data for
the analysis, when the outcomes are different across stud-
ies, and when outcome and covariate data are missing
from included studies [31]. Our recently completed pooled
summary meta-analysis was a successful collaboration of
five principal investigators [1]. In addition to the team
members from these five trials, the principal investigators
of four additional trials have committed to provide data
for the AFFIRM meta-analysis. These are the largest and
most robust trials completed in this area.
The multinational research team has representation
from Canada, the Netherlands, France, Italy, Germany,
and Finland. Almost all review team members attended
the face-to-face IPDMA planning meeting. To protect
against the misclassification of outcomes, the AFFIRM
review team discussed each outcome at this meeting
until consensus on detailed definitions and diagnostic
criteria was reached. Definitions for all variables to be
included in the IPDMA common dataset are docu-
mented in a data dictionary that was reviewed, revised
according to team feedback, and finalized. Despite this,
we recognize that challenges will be encountered due to
variability in how the variables were originally defined
and collected in each of the nine trials. In some cases it
will be necessary to consult the original clinical records
to obtain complete information for the IPDMA which
will be a labor-intensive process. Another challenge is
the diversity in language of the original datasets (English,
French, Dutch, Italian, and German) that will necessitate
translation when the data are recoded. Attention to detail,
careful documentation, and excellent communication
will be instrumental to the successful completion of
this IPDMA.Additional file
Additional file 1: Search strategy.Abbreviations
ASA: Acetylsalicylic acid; ACCP: American college of chest physicians;
DARE: Database of abstracts of reviews of effects; GA: Gestational age;
HELLP: HELLP syndrome (hemolysis, elevated liver enzymes, low platelet
count); HIT: Heparin-induced thrombocytopenia; HTA: Health technology
assessment database; IPDMA: Individual patient data meta-analysis;
ISTH: International society on thrombosis and hemostasis; IUGR:
Intrauterine growth restriction; LMWH: Low-molecular-weight heparin;
PE: Pre-eclampsia; RCT: Randomized controlled trial; SB: Stillbirth;
SGA: Small-for-gestational age.
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